Meanwhile, another two real‐world studies confirmed that low‐dose sacubitril/valsartan significantly reduced N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), induced beneficial cardiac reverse remodeling and improved clinical functional performance in HF patients without severe adverse effect.6, 15. This evidence concerns the gene NPPB and hydrops fetalis.